Form 8-K ACADIA PHARMACEUTICALS For: Dec 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Acadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM ESTMizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining a Neutral rating.
The analyst commented, "Acadia has released top-line data for their pipeline asset trofinetide for the treatment of Rett syndrome. While... More
